Literature DB >> 24777761

Kinetics of porphyrin fluorescence accumulation in pediatric brain tumor cells incubated in 5-aminolevulinic acid.

Michael Schwake1, Dennis Günes, Michaela Köchling, Angela Brentrup, Juliane Schroeteler, Marc Hotfilder, Michael C Fruehwald, Walter Stummer, Christian Ewelt.   

Abstract

BACKGROUND: Fluorescence-guided surgery with 5-aminolevulinic acid (5-ALA) enables more complete resections of tumors in adults. 5-ALA elicits accumulation of fluorescent porphyrins in various cancerous tissues, which can be visualized using a modified neurosurgical microscope with blue light. Although this technique is well established in adults, it has not been investigated systematically in pediatric brain tumors. Specifically, it is unknown how quickly, how long, and to what extent various pediatric tumors accumulate fluorescence. The purpose of this study was to determine utility and time course of 5-ALA-induced fluorescence in typical pediatric brain tumors in vitro.
METHODS: Cell cultures of medulloblastoma [DAOY and UW228], cPNET [PFSK] atypical teratoid rhabdoid tumor [BT16] and ependymoma [RES196] were incubated with 5-ALA for either 60 minutes or continuously. Porphyrin fluorescence intensities were determined using a fluorescence-activated cell sorter (FACS) after 1, 3, 6, 9, 12 and 24 hours. C6 and U87 cells served as controls.
RESULTS: All pediatric brain tumor cell lines displayed fluorescence compared to their respective controls without 5-ALA (p < 0.05). Sixty minutes of incubation resulted in peaks between 3 and 6 hours, whereas continuous incubation resulted in peaks at 12 hours or beyond. 60 minute incubation peak levels were between 52 and 91 % of maxima achieved with continuous incubation. Accumulation and clearance varied between cell types.
CONCLUSIONS: We demonstrate that 5-ALA exposure of cell lines derived from typical pediatric central nervous system (CNS) tumors induces accumulation of fluorescent porphyrins. Differences in uptake and clearance indicate that different application modes may be necessary for fluorescence-guided resection, depending on tumor type.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24777761     DOI: 10.1007/s00701-014-2096-7

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  5 in total

1.  Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.

Authors:  Andrea O Fontana; Deborah Piffaretti; Francesco Marchi; Floriana Burgio; Ana Bela Faia-Torres; Paolo Paganetti; Sandra Pinton; Uwe Pieles; Michael Reinert
Journal:  J Neurooncol       Date:  2017-05-12       Impact factor: 4.130

2.  Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas.

Authors:  Walter Stummer; Herbert Stepp; Otmar D Wiestler; Uwe Pichlmeier
Journal:  Neurosurgery       Date:  2017-08-01       Impact factor: 4.654

3.  Indocyanine-Green for Fluorescence-Guided Surgery of Brain Tumors: Evidence, Techniques, and Practical Experience.

Authors:  Steve S Cho; Ryan Salinas; John Y K Lee
Journal:  Front Surg       Date:  2019-03-12

4.  Predicting the "usefulness" of 5-ALA-derived tumor fluorescence for fluorescence-guided resections in pediatric brain tumors: a European survey.

Authors:  Walter Stummer; Floriano Rodrigues; Philippe Schucht; Matthias Preuss; Dorothee Wiewrodt; Ulf Nestler; Marco Stein; José Manuel Cabezudo Artero; Nunzio Platania; Jane Skjøth-Rasmussen; Alessandro Della Puppa; John Caird; Søren Cortnum; Sam Eljamel; Christian Ewald; Laura González-García; Andrew J Martin; Ante Melada; Aurelia Peraud; Angela Brentrup; Thomas Santarius; Hans Herbert Steiner
Journal:  Acta Neurochir (Wien)       Date:  2014-09-24       Impact factor: 2.216

5.  5-aminolevulinic acid-guided surgery for focal pediatric brainstem gliomas: A preliminary study.

Authors:  Jason Labuschagne
Journal:  Surg Neurol Int       Date:  2020-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.